


FDA APPROVAL OF BOTOX FOR MIGRAINE TREATMENT ATTRIBUTED TO RESEARCH BY WILLIAM BINDER, MD

his is such positive news!" extols William J. Binder, MD, ABFPRS diplomate and AAFPRS member. Dr. Binder is referring to the recent October 15th announcement by the Food and Drug Administration (FDA) that BOTOX has finally been approved for prevention and treatment of chronic migraine headaches.

"Over three million people suffer from chronic migraines and it is estimated that there are over 28 million migraine sufferers in the U.S. alone. The FDA approval of BOTOX for this debilitating condition means that there is finally a viable treatment option," he notes.

Dr. Binder (pictured to the right) is credited with discovering

the effectiveness of BOTOX to prevent the onset of migraine headaches back in the early 1990s. After the drug's intro-



duction into facial plastic surgery practices for treatment of facial wrinkles, Dr. Binder had several patients comment that their migraine headaches disappeared after they had received BOTOX injections. Dr. Binder realized that he might be onto something remarkable.

He began a series of clinical trials that culminated in his discovery that BOTOX, when administered properly, could effectively prevent migraine episodes for up to three or more months in 80 percent of his patients. The injections also provided relief from migraine's sister symptoms which include nausea, vomiting, and sensitivity to light. Dr. Binder's colleagues, Andrew Blitzer, MD; Mitchell Brin, MD; and Larry Schoenrock, MD, also participated in the early clinical studies.

During the course of his clinical trials, Dr. Binder developed the injection protocol that served as the basis for the current FDA approved BOTOX migraine treatment. He went on to present his findings to neurological and surgical academies across the U.S. and Britain and was awarded a U.S. patent for his discovery.

Dr. Binder's groundbreaking research, analysis, and ultimate FDA approval of his findings are yet another distinguished reflection on our specialty's continuing contributions to the field of nedicine.

Editor's Note: This article was written by Laurie Wirth, ABFPRS Executive Director.

WILLIAM J. BINDER, M.D., F.A.C.S.

FACIAL PLASTIC AND RECONSTRUCTIVE SURGERY A Medical Corporation

OFFICE ADDRESS:

William J. Binder M.D., F.A.C.S. 120 S. Spalding Drive, Suite 340 Beverly Hills, CA 90212

OFFICE TELEPHONE:

(310) 858-6749

OFFICE FAX:

(310) 271-9266